Earnings summaries and quarterly performance for Ensysce Biosciences.
Research analysts who have asked questions during Ensysce Biosciences earnings calls.
Recent press releases and 8-K filings for ENSC.
Ensysce Biosciences Initiates PF614 Phase 3 Enrollment and Secures Financing
ENSC
Product Launch
New Projects/Investments
Convertible Preferred Issuance
- Ensysce Biosciences initiated Phase 3 enrollment for PF614, its next-generation extended-release oxycodone prodrug, for moderate to severe post-surgical pain.
- The company secured a new U.S. patent for its MPAR® overdose-protection platform, extending exclusivity through 2042, and received FDA alignment on PF614's manufacturing strategy.
- Ensysce closed a $4 million convertible preferred stock financing, with potential access to an additional $16 million over the next 24 months, to fund PF614's Phase 3 development and other initiatives.
Dec 12, 2025, 1:00 PM
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million Total Funding
ENSC
Debt Issuance
New Projects/Investments
Convertible Preferred Issuance
- Ensysce Biosciences has secured $4 million in convertible preferred stock financing, with the potential for an additional $16 million in future tranches over the next 24 months, bringing the total potential financing to $20 million.
- The initial $4 million capital will primarily accelerate the Phase 3 clinical program for PF614, the company's flagship analgesic candidate.
- The convertible preferred stock has a stated value of $1,100 per share and a conversion price of $2.50 per share, with dividends accruing at 4.0% per annum.
- The financing also includes 50% warrant coverage on each takedown, exercisable at the fixed conversion price of $2.50 per share for five years.
Nov 17, 2025, 10:29 PM
Ensysce Biosciences Reports Q3 2025 Financial Results and Clinical Milestones
ENSC
Earnings
New Projects/Investments
Convertible Preferred Issuance
- Ensysce Biosciences reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024, with research and development expenses increasing to $3.0 million from $1.7 million.
- As of September 30, 2025, cash and cash equivalents were $1.7 million. In November 2025, the company completed a convertible preferred stock offering raising $4 million in gross proceeds, with potential for an additional $16 million in future funding.
- Operationally, Ensysce initiated its pivotal Phase 3 PF614-301 clinical trial in July 2025 and received encouraging feedback from the FDA regarding its PF614-MPAR program, including support for overdose protection labeling and a potential streamlined 505(b)(2) regulatory pathway.
Nov 14, 2025, 9:15 PM
Quarterly earnings call transcripts for Ensysce Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more